Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Retained Earnings (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Retained Earnings data on record, last reported at -$967.8 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 7.19% year-over-year to -$967.8 million; the TTM value through Dec 2025 reached -$967.8 million, down 7.19%, while the annual FY2025 figure was -$967.8 million, 7.19% down from the prior year.
  • Retained Earnings reached -$967.8 million in Q4 2025 per ACRS's latest filing, down from $597000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $597000.0 in Q3 2025 and bottomed at -$967.8 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$367.5 million, with a median of -$267.3 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 1134772.34% in 2021, then skyrocketed 204.1% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$224000.0 in 2021, then tumbled by 300.45% to -$897000.0 in 2022, then surged by 88.18% to -$106000.0 in 2023, then tumbled by 851655.66% to -$902.9 million in 2024, then dropped by 7.19% to -$967.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$967.8 million in Q4 2025, $597000.0 in Q3 2025, and $482000.0 in Q2 2025.